Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CGEM |
---|---|---|
09:32 ET | 4945 | 12.14 |
09:33 ET | 4389 | 12.33 |
09:35 ET | 2500 | 12.205 |
09:37 ET | 732 | 12.3 |
09:39 ET | 890 | 12.34 |
09:42 ET | 15119 | 12.35 |
09:46 ET | 200 | 12.385 |
09:48 ET | 1300 | 12.34 |
09:50 ET | 1720 | 12.42 |
09:51 ET | 400 | 12.34 |
09:53 ET | 3000 | 12.44 |
09:55 ET | 2914 | 12.36 |
09:57 ET | 600 | 12.26 |
10:04 ET | 1523 | 12.195 |
10:06 ET | 600 | 12.24 |
10:08 ET | 927 | 12.32 |
10:09 ET | 1214 | 12.365 |
10:11 ET | 1661 | 12.3 |
10:13 ET | 100 | 12.29 |
10:15 ET | 100 | 12.29 |
10:18 ET | 100 | 12.285 |
10:20 ET | 300 | 12.29 |
10:22 ET | 100 | 12.29 |
10:24 ET | 316 | 12.345 |
10:26 ET | 1336 | 12.345 |
10:27 ET | 4542 | 12.3 |
10:29 ET | 2700 | 12.35 |
10:31 ET | 1100 | 12.325 |
10:33 ET | 2149 | 12.305 |
10:36 ET | 300 | 12.31 |
10:38 ET | 200 | 12.325 |
10:40 ET | 3608 | 12.34 |
10:42 ET | 100 | 12.37 |
10:44 ET | 9113 | 12.385 |
10:45 ET | 5532 | 12.29 |
10:51 ET | 1500 | 12.27 |
10:54 ET | 400 | 12.295 |
10:56 ET | 3593 | 12.24 |
10:58 ET | 4368 | 12.21 |
11:00 ET | 2968 | 12.19 |
11:02 ET | 4762 | 12.18 |
11:03 ET | 1154 | 12.17 |
11:05 ET | 2408 | 12.15 |
11:07 ET | 2187 | 12.25 |
11:09 ET | 800 | 12.34 |
11:12 ET | 200 | 12.325 |
11:14 ET | 1500 | 12.265 |
11:20 ET | 500 | 12.32 |
11:21 ET | 300 | 12.35 |
11:23 ET | 1800 | 12.36 |
11:25 ET | 1000 | 12.35 |
11:27 ET | 1362 | 12.35 |
11:30 ET | 17990 | 12.39 |
11:32 ET | 2635 | 12.54 |
11:34 ET | 2245 | 12.5 |
11:36 ET | 100 | 12.49 |
11:38 ET | 2000 | 12.59 |
11:39 ET | 300 | 12.62 |
11:41 ET | 200 | 12.62 |
11:43 ET | 300 | 12.68 |
11:45 ET | 1000 | 12.605 |
11:48 ET | 900 | 12.605 |
11:50 ET | 100 | 12.67 |
11:52 ET | 1500 | 12.68 |
11:54 ET | 200 | 12.66 |
11:56 ET | 12433 | 12.64 |
11:59 ET | 100 | 12.7 |
12:03 ET | 309 | 12.7 |
12:06 ET | 500 | 12.7 |
12:08 ET | 5361 | 12.6 |
12:10 ET | 2329 | 12.61 |
12:14 ET | 600 | 12.64 |
12:19 ET | 871 | 12.685 |
12:21 ET | 1311 | 12.68 |
12:24 ET | 100 | 12.69 |
12:26 ET | 386 | 12.69 |
12:30 ET | 1100 | 12.68 |
12:32 ET | 1100 | 12.66 |
12:33 ET | 200 | 12.64 |
12:35 ET | 250 | 12.63 |
12:42 ET | 719 | 12.64 |
12:44 ET | 300 | 12.68 |
12:46 ET | 300 | 12.67 |
12:48 ET | 4536 | 12.6 |
12:50 ET | 2900 | 12.5884 |
12:51 ET | 700 | 12.55 |
12:53 ET | 248 | 12.53 |
12:55 ET | 100 | 12.53 |
12:57 ET | 100 | 12.49 |
01:00 ET | 100 | 12.5 |
01:02 ET | 800 | 12.47 |
01:04 ET | 540 | 12.51 |
01:09 ET | 200 | 12.57 |
01:11 ET | 852 | 12.61 |
01:13 ET | 100 | 12.62 |
01:15 ET | 400 | 12.64 |
01:20 ET | 100 | 12.62 |
01:22 ET | 422 | 12.64 |
01:24 ET | 300 | 12.615 |
01:26 ET | 1906 | 12.605 |
01:29 ET | 768 | 12.605 |
01:33 ET | 1000 | 12.64 |
01:36 ET | 800 | 12.67 |
01:38 ET | 700 | 12.68 |
01:40 ET | 3447 | 12.61 |
01:44 ET | 700 | 12.58 |
01:45 ET | 587 | 12.5739 |
01:47 ET | 200 | 12.63 |
01:49 ET | 100 | 12.625 |
01:51 ET | 1029 | 12.625 |
01:54 ET | 881 | 12.59 |
01:58 ET | 821 | 12.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cullinan Therapeutics Inc | 711.5M | -4.4x | --- |
Oruka Therapeutics Inc | 717.5M | -3.4x | --- |
CARGO Therapeutics Inc | 722.1M | -4.8x | --- |
Oculis Holding AG | 615.7M | -7.3x | --- |
Erasca Inc | 734.5M | -3.3x | --- |
Replimune Group Inc | 755.0M | -5.2x | --- |
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $711.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.17 |
EPS | $-2.88 |
Book Value | $10.58 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.